Bristol-Myers Squibb Q2 2026 Earnings Analysis

More earnings analysis: https://betafinch.comGroups: PHARMA (https://betafinch.com/groups/PHARMA)──────────ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown! Today we're digging into Bristol Myers Squibb's second quarter 2026 results, reported Thursday morning. Before we get into it, quick disclaimer: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.JORDAN: And BMY shares were up nearly 2.8% on the news, so investors clearly liked what they heard. Let's get into the numbers.ALEX: Total revenue for Q2 came in around $13 billion, up 5% year-over-year. The headline story here is what they call the "growth portfolio" — that's their newer drugs — now making up almost 60% of total revenue, growing 14%. Ten different products posted double-digit growth.JORDAN: That's the story management really wants you to hear — they're successfully transitioning away from legacy products losing patent protection, toward newer assets. And the standouts were impressive: Reblozyl up 29%, Breyanzi up 41%, Camzyos up 59%, and Qvantig — the newer version of their big cancer drug Opdivo — now annualizing over $1 billion.ALEX: Meanwhile, on the "legacy" side, Eliquis, their blood thinner, actually grew 21% on strong demand, which helped offset declines elsewhere from generic competition, especially as Revlimid keeps facing generics.JORDAN: Diluted EPS was $2.04 for the quarter, and gross margin held at 71.4%. And because of this strength, management raised full-year guidance for both revenue and adjusted EPS.ALEX: They also raised their Eliquis growth expectation for the year to 20-25%, and said the overall legacy portfolio decline will be less severe than previously thought — now 4-6% instead of worse.JORDAN: Balance sheet's solid too — $11.5 billion in cash, $3.4 billion in operating cash flow for the quarter, and they paid down $1.2 billion in debt. So they've got room to keep investing.ALEX: Now let's talk strategy, because there's a lot happening on the pipeline side. CEO Chris Boerner talked about the company potentially launching more than 10 new medicines by the end of the decade, plus over 30 lifecycle management opportunities.JORDAN: The near-term catalyst everyone's watching is iberdomide — that's their CELMoD, a new class of oral drug for multiple myeloma. It has an FDA decision date of August 17th, so basically two weeks after this call. If approved, it'd be the first commercialized CELMoD ever.ALEX: And there's a second one right behind it — mezigdomide — which just got its FDA application accepted with a target decision date of May 2027. Management's pretty bullish these two drugs, along with a third one called golcadomide, could eventually replace older myeloma standards like Revlimid and Pomalyst.JORDAN: But here's the more nuanced part of the call — two of their biggest pipeline bets just got delayed. Milvexian, a next-generation blood thinner they're developing with Johnson & Johnson... wait, actually it's with partners on the anticoagulant side, competing against their own Eliquis franchise — its atrial fibrillation trial readout got pushed from late 2026 to Q1 2027.ALEX: And separately, Cobenfy — their schizophrenia drug that they're also testing in Alzheimer's-related psychosis — those readouts are now expected to start in early 2027 instead of this year.JORDAN: Now, management was pretty insistent both delays are actually good news in disguise. For milvexian, it's an event-driven trial — meaning they need a certain number of stroke and bleeding events to occur before they can read the data. Fewer events happening means the drug might be working better than expected. Chief Medical Officer Cristian Massacesi even pointed out that a competitor's similar trial got stopped early for going the wThis episode includes AI-generated content.